Entyvio 300 MG vials
Ended Awarded
- Contract number
- SPE2DB25FY23Q
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,670
Award facts
- Contract value 100% obligated
- $29,669.58 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $29,669.58 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on September 25, 2025, for the supply of Entyvio 300 mg vials, with an ultimate completion date of October 17, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected without a set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and valid through November 2026, which enables the agency to procure a comprehensive range of pharmaceutical products to support medical supply needs across Department of Defense healthcare facilities worldwide.
Entyvio (vedolizumab) is a biologic medication primarily used to treat inflammatory bowel diseases, including ulcerative colitis and Crohn's disease, making this delivery order part of the Defense Logistics Agency's broader pharmaceutical supply chain supporting military healthcare systems. DMS Pharmaceutical Group has established itself as a critical supplier of specialty pharmaceuticals and biologics to federal agencies, with a demonstrated portfolio of contract awards covering oncology treatments, vaccines, and other specialized medications. The firm fixed-price structure and compressed delivery timeline reflect the agency's need for rapid procurement of this pharmaceutical product to meet Department of Defense medical requirements.
Quick answers
Who was awarded contract SPE2DB25FY23Q?
SPE2DB25FY23Q was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on September 25, 2025.
How much is contract SPE2DB25FY23Q worth?
The government has obligated $29,670 on SPE2DB25FY23Q.
Is contract SPE2DB25FY23Q an order under another contract?
Yes. SPE2DB25FY23Q is a delivery order under SPE2DB22D9362, an indefinite delivery contract.
Was contract SPE2DB25FY23Q competed?
The extent of competition for SPE2DB25FY23Q was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award